Established venous thromboembolism therapies: Heparin, low molecular weight heparins, and vitamin K antagonists, with a discussion of heparin-induced thrombocytopenia

Clinics in Chest Medicine

Volumn 31, Issue 4, 2010, Pages 691-706

  Pendleton, Robert C ^a   Rodgers, George M ^a,b   Hull, Russell D ^c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF CALGARY   (Canada)

Author keywords

Heparin; Heparin induced thrombocytopenia; Low molecular weight heparin; Venous thromboembolism; Vitamin K antagonist; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; DALTEPARIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; SEROTONIN; THROMBIN INHIBITOR; TINZAPARIN; WARFARIN;

ANAPHYLAXIS; ARTERY THROMBOSIS; BLEEDING; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSAGE SCHEDULE COMPARISON; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG CLEARANCE; DRUG CONTAMINATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GANGRENE; HEPARIN INDUCED THROMBOCYTOPENIA; HEPARIN INDUCED THROMBOSIS; HOME CARE; HUMAN; INJECTION SITE REACTION; INTERNATIONAL NORMALIZED RATIO; KIDNEY DYSFUNCTION; LABORATORY TEST; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; NONHUMAN; OBESITY; PARTIAL THROMBOPLASTIN TIME; PATHOGENESIS; PATIENT SATISFACTION; PHARMACODYNAMICS; PHARMACOGENETICS; POSTTHROMBOSIS SYNDROME; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SEROTONIN RELEASE; SKIN NECROSIS; THROMBOCYTE COUNT; THROMBOSIS; TREATMENT DURATION; TREATMENT PLANNING; VENOUS THROMBOEMBOLISM;

HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 78049477678     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccm.2010.07.003     Document Type: Review

References (109)

1. Galson S.K., U.S.Department of Health & Human Services The surgeon general's call to action to prevent deep vein thrombosis and pulmonary embolism 2008 Available at:, Accessed January 25, 2010. http://www.surgeongeneral.gov/topics/deepvein/.
2. Barritt D.W., Jordan S.C. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960, 1(7138):1309-1312.
3. Prevention and treatment of venous thromboembolism. International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006, 25(2):101-161.
4. Snow V., Qaseem A., Barry P., et al. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007, 146(3):204-210.
5. Kearon C., Kahn S.R., Agnelli G., et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):454S-545S.
6. Ansell J., Hirsh J., Hylek E., et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):160S-198S.
7. Wessler S., Reiner L., Freiman D.G., et al. Serum-induced thrombosis. Studies of its induction, and evolution under controlled conditions in vivo. Circulation 1959, 20:864-874.
8. Brandjes D.P., Heijboer H., Buller H.R., et al. Acenocoumarol and heparin compared with acenocoumarol alone in the initial treatment of proximal-vein thrombosis. N Engl J Med 1992, 327(21):1485-1489.
9. Gallus A., Jackaman J., Tillett J., et al. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986, 2(8519):1293-1296.
10. Hull R.D., Raskob G.E., Rosenbloom D., et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990, 322(18):1260-1264.
11. Wardrop D., Keeling D. The story of the discovery of heparin and warfarin. Br J Haematol 2008, 141(6):757-763.
12. Hirsh J., Bauer K.A., Donati M.B., et al. Parenteral anticoagulants: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):141S-159S.
13. U.S.Food and Drug Administration Public health advisory: important warnings and instructions for heparin sodium injection (Baxter) FDA Web site. Available at:, Accessed February 17, 2010. http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051133.html.
14. U.S.Food and Drug Administration Update to healthcare facilities and healthcare professionals about heparin and heparin-containing medical products FDA Web site. Available at:, Accessed February 17, 2010. http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm135355.htm.
15. Guerrini M., Beccati D., Shriver Z., et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008, 26(6):669-675.
16. Kishimoto T.K., Viswanathan K., Ganguly T., et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008, 358(23):2457-2467.
17. U.S.Food and Drug Administration FDA Public health alert: change in heparin USP monograph FDA Web site. Available at:, Accessed February 17, 2010. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm184502.htm.
18. Hommes D.W., Bura A., Mazzolai L., et al. Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med 1992, 116(4):279-284.
19. Cruickshank M.K., Levine M.N., Hirsh J., et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991, 151(2):333-337.
20. Raschke R.A., Gollihare B., Peirce J.C. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996, 156(15):1645-1649.
21. Raschke R.A., Reilly B.M., Guidry J.R., et al. The weight-based heparin dosing nomogram compared with a " standard care" nomogram. A randomized controlled trial. Ann Intern Med 1993, 119(9):874-881.
22. Anand S., Ginsberg J.S., Kearon C., et al. The relation between the activated partial thromboplastin time response and recurrence in patients with venous thrombosis treated with continuous intravenous heparin. Arch Intern Med 1996, 156(15):1677-1681.
23. Anand S.S., Bates S., Ginsberg J.S., et al. Recurrent venous thrombosis and heparin therapy: an evaluation of the importance of early activated partial thromboplastin times. Arch Intern Med 1999, 159(17):2029-2032.
24. Hull R.D., Raskob G.E., Brant R.F., et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Intern Med 1997, 157(22):2562-2568.
25. Hull R.D., Raskob G.E., Hirsh J., et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986, 315(18):1109-1114.
26. Writing Committee for the Galilei Investigators Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism. Arch Intern Med 2004, 164(10):1077-1083.
27. Kearon C., Ginsberg J.S., Julian J.A., et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006, 296(8):935-942.
28. Weitz J.I. Low-molecular-weight heparins. N Engl J Med 1997, 337(10):688-698.
29. Hull R.D., Raskob G.E., Pineo G.F., et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis. N Engl J Med 1992, 326(15):975-982.
30. Prandoni P., Lensing A.W., Buller H.R., et al. Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis. Lancet 1992, 339(8791):441-445.
31. Dolovich L.R., Ginsberg J.S., Douketis J.D., et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000, 160(2):181-188.
32. Quinlan D.J., McQuillan A., Eikelboom J.W. Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials. Ann Intern Med 2004, 140(3):175-183.
33. Akl E.A., Rohilla S., Barba M., et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, 1. CD006649.
34. van Dongen C.J., MacGillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2005, 1. CD003074.
35. Merli G., Spiro T.E., Olsson C.G., et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001, 134(3):191-202.
36. Nutescu E.A., Spinler S.A., Wittkowsky A., et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother 2009, 43(6):1064-1083.
37. Rondina M.T., Pendleton R.C., Wheeler M., et al. The treatment of venous thromboembolism in special populations. Thromb Res 2007, 119(4):391-402.
38. Bazinet A., Almanric K., Brunet C., et al. Dosage of enoxaparin among obese and renal impairment patients. Thromb Res 2005, 116(1):41-50.
39. Hainer J.W., Barrett J.S., Assaid C.A., et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002, 87(5):817-823.
40. Wilson S.J., Wilbur K., Burton E., et al. Effect of patient weight on the anticoagulant response to adjusted therapeutic dosage of low-molecular-weight heparin for the treatment of venous thromboembolism. Haemostasis 2001, 31(1):42-48.
41. Spinler S.A., Inverso S.M., Cohen M., et al. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. Am Heart J 2003, 146(1):33-41.
42. Falga C., Capdevila J.A., Soler S., et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost 2007, 98(4):771-776.
43. Lim W., Dentali F., Eikelboom J.W., et al. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006, 144(9):673-684.
44. Product Information Lovenox (enoxaparin sodium injection) 2009, Sanofi-aventis US LLC, Bridgewater (NJ).
45. Bates S.M., Greer I.A., Pabinger I., et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):844S-886S.
46. Koopman M.M., Prandoni P., Piovella F., et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996, 334(11):682-687.
47. Levine M., Gent M., Hirsh J., et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996, 334(11):677-681.
48. O'Brien B., Levine M., Willan A., et al. Economic evaluation of outpatient treatment with low-molecular-weight heparin for proximal vein thrombosis. Arch Intern Med 1999, 159(19):2298-2304.
49. Douketis J.D. Treatment of deep vein thrombosis: what factors determine appropriate treatment?. Can Fam Physician 2005, 51:217-223.
50. Douketis J.D., Kearon C., Bates S., et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998, 279(6):458-462.
51. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999, 353(9162):1386-1389.
52. Becattini C., Vedovati M.C., Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007, 116(4):427-433.
53. Goldhaber S.Z. Echocardiography in the management of pulmonary embolism. Ann Intern Med 2002, 136(9):691-700.
54. Jimenez D., Yusen R.D., Otero R., et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest 2007, 132(1):24-30.
55. Klok F.A., Mos I.C., Huisman M.V. Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolism: a systematic review and meta-analysis. Am J Respir Crit Care Med 2008, 178(4):425-430.
56. Schoepf U.J., Kucher N., Kipfmueller F., et al. Right ventricular enlargement on chest computed tomography: a predictor of early death in acute pulmonary embolism. Circulation 2004, 110(20):3276-3280.
57. Janjua M., Badshah A., Matta F., et al. Treatment of acute pulmonary embolism as outpatients or following early discharge. A systematic review. Thromb Haemost 2008, 100(5):756-761.
58. Squizzato A., Galli M., Dentali F., et al. Outpatient treatment and early discharge of symptomatic pulmonary embolism: a systematic review. Eur Respir J 2009, 33(5):1148-1155.
59. Otero R., Uresandi F., Jimenez D., et al. Home treatment in pulmonary embolism. Thromb Res 2010, 126(1):e1-e5.
60. Stein P.D., Hull R.D., Matta F., et al. Early discharge of patients with venous thromboembolism: implications regarding therapy. Clin Appl Thromb Hemost 2010, 16(2):141-145.
61. Aujesky D., Stone R.A., Kim S., et al. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: a statewide perspective. Arch Intern Med 2008, 168(7):706-712.
62. Hull R., Delmore T., Genton E., et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979, 301(16):855-858.
63. Lagerstedt C.I., Olsson C.G., Fagher B.O., et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985, 2(8454):515-518.
64. Wessler S., Gitel S.N. Warfarin. From bedside to bench. N Engl J Med 1984, 311(10):645-652.
65. Hirsh J., Bates S.M. Clinical trials that have influenced the treatment of venous thromboembolism: a historical perspective. Ann Intern Med 2001, 134(5):409-417.
66. Hull R., Hirsh J., Jay R., et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982, 307(27):1676-1681.
67. Crowther M.A., Ginsberg J.B., Kearon C., et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999, 159(1):46-48.
68. Harrison L., Johnston M., Massicotte M.P., et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997, 126(2):133-136.
69. Kovacs M.J., Rodger M., Anderson D.R., et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003, 138(9):714-719.
70. Sanderson S., Emery J., Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005, 7(2):97-104.
71. Rieder M.J., Reiner A.P., Gage B.F., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005, 352(22):2285-2293.
72. Grice G.R., Laramie D., Anderson D.C. Periprocedural anticoagulation management in orthopedic patients: overview and description of a program utilizing pharmacogenetics. J Clin Outcome Manag 2008, 15(4):183-190.
73. McWilliam A, Lutter R, Nardinelli C AEI-Brookings joint center regulatory studies report: health care savings from personalized medicine using genetic testing Available at:, Accessed January 25, 2010. http://www.aei-brookings.org/publications/abstract.php%3Fpid%3D1127.
74. Anderson J.L., Horne B.D., Stevens S.M., et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 2007, 116(22):2563-2570.
75. Caraco Y., Blotnick S., Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 2008, 83(3):460-470.
76. Eckman M.H., Rosand J., Greenberg S.M., et al. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med 2009, 150(2):73-83.
77. Rosove M.H., Grody W.W. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. Ann Intern Med 2009, 151(4):270-273. W295.
78. Dentali F., Manfredi E., Crowther M., et al. Long-duration therapy with low molecular weight heparin in patients with antiphospholipid antibody syndrome resistant to warfarin therapy. J Thromb Haemost 2005, 3(9):2121-2123.
79. Luk C., Wells P.S., Anderson D., et al. Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001, 111(4):270-273.
80. Osinbowale O., Al Malki M., Schade A., et al. An algorithm for managing warfarin resistance. Cleve Clin J Med 2009, 76(12):724-730.
81. Lee A.Y. Cancer and venous thromboembolism: prevention, treatment and survival. J Thromb Thrombolysis 2008, 25(1):33-36.
82. Prandoni P., Lensing A.W., Piccioli A., et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002, 100(10):3484-3488.
83. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003, 349(2):146-153.
84. Hull R.D., Pineo G.F., Brant R.F., et al. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006, 119(12):1062-1072.
85. Akl E.A., Barba M., Rohilla S., et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008, 2. CD006650.
86. Noble S.I., Finlay I.G. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Pa Med 2005, 19(3):197-201.
87. National Comprehensive Cancer Network NCCN Clinical practice guidelines in oncology. Venous thromboembolic disease, V.2.2009 Available at:, Accessed January 25, 2010. http://www.nccn.org.
88. Lyman G.H., Khorana A.A., Falanga A., et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007, 25(34):5490-5505.
89. Mandala M., Falanga A., Roila F. Management of venous thromboembolism in cancer patients: ESMO clinical recommendations. Ann Oncol 2009, 20(Suppl 4):182-184.
90. van der Heijden J.F., Hutten B.A., Buller H.R., et al. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev 2002, 1. CD002001.
91. Hull R.D., Pineo G.F., Brant R.F., et al. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 2007, 120(1):72-82.
92. Marchetti M., Pistorio A., Barone M., et al. Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: a cost-effectiveness analysis. Am J Med 2001, 111(2):130-139.
93. Hull R.D., Pineo G.F., Brant R., et al. Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome. Am J Med 2009, 122(8):762-769. e763.
94. Romera A., Cairols M.A., Vila-Coll R., et al. A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 2009, 37(3):349-356.
95. Daskalopoulos M.E., Daskalopoulou S.S., Tzortzis E., et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 2005, 29(6):638-650.
96. Lopez-Beret P., Orgaz A., Fontcuberta J., et al. Low molecular weight heparin versus oral anticoagulants in the long-term treatment of deep venous thrombosis. J Vasc Surg 2001, 33(1):77-90.
97. Prandoni P., Frulla M., Sartor D., et al. Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost 2005, 3(2):401-402.
98. Shbaklo H., Holcroft C.A., Kahn S.R. Levels of inflammatory markers and the development of the post-thrombotic syndrome. Thromb Haemost 2009, 101(3):505-512.
99. Prandoni P., Kahn S.R. Post-thrombotic syndrome: prevalence, prognostication and need for progress. Br J Haematol 2009, 145(3):286-295.
100. Amiral J., Bridey F., Dreyfus M., et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 1992, 68(1):95-96.
101. Warkentin T.E., Hayward C.P., Boshkov L.K., et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994, 84(11):3691-3699.
102. Warkentin T.E. Clinical picture of heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2008, 21-66. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
103. Lee D.H., Warkentin T.E. Frequency of heparin-induced thrombocytopenia. Heparin-induced Thrombocytopenia 2008, 67-116. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
104. Warkentin T.E., Kelton J.G. A 14-year study of heparin-induced thrombocytopenia. Am J Med 1996, 101(5):502-507.
105. Lo G.K., Juhl D., Warkentin T.E., et al. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost 2006, 4(4):759-765.
106. Warkentin T.E. Laboratory testing for heparin-induced thrombocytopenia. Heparin-induced thrombocytopenia 2008, 227-260. Informa Healthcare USA, Inc, New York. 4th edition. T.E. Warkentin, A. Greinacher (Eds.).
107. Bakchoul T., Giptner A., Najaoui A., et al. Prospective evaluation of PF4/heparin immunoassays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost 2009, 7(8):1260-1265.
108. Zwicker J.I., Uhl L., Huang W.Y., et al. Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. J Thromb Haemost 2004, 2(12):2133-2137.
109. Warkentin T.E., Greinacher A., Koster A., et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008, 133(Suppl 6):340S-380S.